Nice setup in $KPTI, I suggest buying these names with small positions considering the volatility that can occur after catalysts when new data is released, or around FDA approvals, etc.
Upside can be substantial though, so if technicals and fundamentals align, it's worth keeping some exposure.
Best of luck!
Cheers,
Ivan Labrie.
Falling wedge idea for KPTI.
Areas above the arrows up are very similar hence I propose a breakout of the falling wedge is coming.
Falling wedges are considered a bullish pattern.
NASDAQ:KPTI
Possible Scenario: Long
Evidence: Price Action, IH&S, Money-Flow
TP1: 7.85$
Call options, 01/21/2022, Strike 7.5$
*This is my idea and could be wrong 100%
Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma
SHANGHAI and HONG KONG, April 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global...
This one was brought to my attention by California Hip Hop Rap Underrated during ChampionVibe's Livestream a few days ago. I see this withing a channel while maybe looking left it could also look like a ascending broadening wedge which should be taken into account. Risk management is easy here and there is an edge for the bulls on the osciliators so I will play...
The chart is consolidating in range of 14 after having made a huge cup and coning out of handle pattern, may start uprun towards 20, SL:13.75. Once the cup and handle pattern give successful breakout near 20, may cross 30.
Disclaimer: The stock/index/currency discussed do not constitute Investment/trading advise and is merely an effort towards enhancing learning,...
KPTI has been trading in a range with Earnings expected on Feb. 11. Experts expect KPTI to grow exponentially over next few years. At worst, swing this from 15 - 17.5. At best, buy at 15 and hold until breakout.
KPTI: Karyopharm Therapeutics Inc.
2020-12-18 11:30:00
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
KPTI: Karyopharm Therapeutics Inc.
2020-06-22 11:25:10
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
